11 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Heart OMics in AGEing (HOMAGE)
Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,
As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet
22
Participants partenaires
TERMINÉ
Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Voir le projet
11
Participants partenaires
TERMINÉ
The MEtabolic Road to DIAstolic Heart Failure (MEDIA)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,
More than 50% of heart failure (HF) patients present without a major deficit of left ventricular (LV) systolic function and are presumed to suffer from diastolic HF (DHF) because diastolic LV distensibility is usually impaired in these patients. The vast majority (~80%) of DHF patients is exposed to metabolic risk factors. The MEDIA consortium therefore investigates:1) how metabolic derangements c ...
Voir le projet
23
Participants partenaires
TERMINÉ
ROLE OF THE TRANSCRIPTION FACTOR FOXP1 IN B CELL FUNCTION AND LYMPHOMAGENESIS (LYMFOXP1)
Date du début: 1 nov. 2013, Date de fin: 8 avr. 2016,
"FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that has been demonstrated to be expressed in a subset of activated B-cell type (ABC) diffuse B-cell lymphomas (DLBCLs). Strong FOXP1 expression appears to have an additive adverse role in the pathogenesis and clinical behavior of ABC-DLBCL. We believe that a better understanding of the molecular impact of FOXP1 deregulation in DLBCL ...
Voir le projet
1
Participant partenaire
TERMINÉ
Augmenting PBGD expression in the liver as a Novel Gene therapy for Acute Intermittent Porphyria (AIPGENE)
Date du début: 1 janv. 2011, Date de fin: 31 oct. 2014,
Acute intermittent porphyria (AIP) is a rare genetic disease in which mutations in the porphobilinogen deaminase (PBGD) gene produce insufficient activity of a protein necessary for heme synthesis. This leads to an accumulation of toxic intermediates resulting in a wide variety of problems including acute, severe abdominal pains, psychiatric and neurological disorders, and muscular weakness. Acute ...
Voir le projet
8
Participants partenaires
TERMINÉ
Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis (CURELUNG)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2014,
"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understan ...
Voir le projet
11
Participants partenaires
TERMINÉ
Host and viral factors in acute hepatitis C (HEPACUTE)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,
Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.The major objectives o ...
Voir le projet
17
Participants partenaires
TERMINÉ
Evaluation of metastatic and angiogenic potential of cancer stem-like cells in distinct mouse models for lung and liver metastasis (Metastasis)
Date du début: 1 nov. 2011, Date de fin: 5 mars 2014,
Metastasis disease is the leading cause of cancer-related mortality with very few effective treatment options available for patients. Metastases are characterized by the presence of vascular proliferation, a subpopulation of stem-like cells and infiltration by various bone marrow derive cells (BMDCs). BMDCs have been shown to provide the premetastatic niches that promote the angiogenic process a ...
Voir le projet
1
Participant partenaire
TERMINÉ
Restorative Plasticity At Corticostriatal Excitatory Synapses (REPLACES)
Date du début: 1 nov. 2008, Date de fin: 30 avr. 2013,
"Long-lasting, activity-dependent synaptic changes are thought to underlie the ability of the brain to translate experiences into memories and seem to represent the cellular model underlying learning and memory processes. Alteration of brain plasticity may lead to the motor and cognitive disturbances observed in neurodegenerative diseases. Therapeutic approaches targeting synaptic plasticity could ...
Voir le projet
12
Participants partenaires
TERMINÉ
NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN (BrainCAV)
Date du début: 1 oct. 2008, Date de fin: 31 mars 2013,
Formidable challenges remain to prevent and treat successfully neurodegenerative diseases. Traditional pharmacological approaches, as well as those using stem cells, have made progress but their impact remain limited. As suggested by clinical results in Canavan and Parkinson’s disease, gene transfer offers substantial potential. However, this strategy of therapeutic intervention also brings unique ...
Voir le projet
12
Participants partenaires
TERMINÉ
European Network for Cell Imaging and Tracking Expertise (ENCITE)
Date du début: 1 juin 2008, Date de fin: 30 nov. 2012,
"Cell therapy can be defined as the transplantation of living cells for the treatment of medical disorders. Three different principles underlie the increasing interest in cell therapy. 1. Transplanted cells used as an “active drug” 2. Transplanted cells used to replace damaged and degenerated tissue. 3. Cells used as a drug delivery vehicle. Promising results have been obtained in pre-clinical and ...
Voir le projet